Business Wire

NTHU and DAICEL of Japan to Jointly Develop Revolutionary Desktop Chemical Plant

28.10.2021 12:00:00 EEST | Business Wire | Press release

Share

National Tsing Hua University (NTHU) and the well-known Japanese chemical company DAICEL announce a five-year joint project to integrate an innovative microfluidic system developed by scholar Kitamori Takehiko into the chemical manufacturing industry today. Total investment in the project is 450 million Japanese yen (approximately NT$110 million), and its potential to reduce energy consumption while lowering the production of carbon and waste is expected to set a new standard for sustainability in the chemical industry.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211028005388/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Prof. Kitamori Takehiko has developed an innovative microfluidic system which allows the mixing and extracting operations conventionally carried out with large-scale equipment to be performed using a glass chip the size of a business card. (Photo: National Tsing Hua University)

Prof. Kitamori, a world-renowned pioneer in microfluidic and nanofluidic technology and the former vice president of the University of Tokyo, has been serving as the Yushan Honorary Chair Professor of the Institute of Nanoengineering and Microsystems, Department of Power Mechanical Engineering at NTHU since 2020. Building on his previous research conducted at the University of Tokyo, he has developed an innovative microfluidic system which allows the mixing and extracting operations conventionally carried out with large-scale equipment to be performed using a glass chip the size of a business card and capable of combining thousands of microfluidic chips simultaneously, making it possible to create a “desktop chemical plant.”

Kitamori explained that it can be quite difficult to instantaneously mix several large barrels of chemicals with different temperatures and reaction speeds, and there may even be an explosion if the materials are not handled carefully. Thus the preferred way of blending chemicals is by passing it through a microchannel, which makes it possible to precisely control the amount of raw materials used, as well as the mixing sequence and conditions, thereby optimizing the quality of the final product.

Kitamori said that the aim of the project is to reduce the size of chemical production equipment, so that what is currently produced by a factory measuring 20 x 20 meters can be miniaturized into a system only two square meters in size. What’s more, such a system would use less energy and materials, making it less expensive, and would also produce less carbon.

Years ago, when DAICEL president Ogawa Yoshimi heard about the microfluidic technology developed by Kitamori, he was deeply impressed, and is now highly pleased that DAICEL is going to integrate this innovative technology into its operations. He is also looking forward to cooperating with NTHU in introducing this epoch-making manufacturing process to the world, which he also sees as a way of promoting sustainability and the circular economy.

Dr. Fan-gang Tseng, Vice President and Director of Research and Development, NTHU, said that he is very optimistic about the future development of the microfluidic chemical plant. He pointed out that the adoption of this microfluidic process by DAICEL—one of the largest chemical companies in Japan—and by Taiwan’s many small and medium-sized chemical factories would constitute a revolutionary leap forward, and could lead to similar processes being applied by the semiconductor and biomedical industry.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Holly Hsueh
NTHU
(886)3-5162006
hoyu@mx.nthu.edu.tw

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Vertex to Acquire Crinetics Pharmaceuticals6.7.2026 23:04:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a global pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases, today announced that the companies have entered into a definitive agreement under which Vertex will acquire Crinetics for $85.00 per share in cash, for a total equity value of approximately $10.0 billion, or approximately $8.8 billion net of estimated cash acquired. The transaction was unanimously approved by both the Vertex and Crinetics Boards of Directors and is anticipated to close in the third quarter of 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706876183/en/ Crinetics’ marketed medicine, PALSONIFY® (paltusotine), received approval from the U.S. Food and Drug Administration (FDA) in September 2025. PALSONIFY was recently approved by the European Medicines Agency (EMA) a

Ciauru Wins the Second Edition of the Reply AI Music Contest, the International Competition Dedicated to Experimentation Across AI, Music and Live Performance6.7.2026 21:30:00 EEST | Press release

The second edition of the Reply AI Music Contest, the international competition created by Reply to explore new forms of expression combining artificial intelligence, music and live performance, concluded with the announcement of the winner on the Nova Stage powered by Reply during Kappa FuturFestival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706007611/en/ The second edition of the Reply AI Music Contest, the international competition created by Reply to explore new forms of expression combining artificial intelligence, music and live performance, concluded with the announcement of the winner on the Nova Stage powered by Reply during Kappa FuturFestival First place went to Ciauru, the stage name of Simone Privitera, an Italian multi-platinum DJ and producer who integrates artificial intelligence tools into a musical practice rooted in the contemporary electronic scene. With a career that has seen him collaborate wit

Rimini Street to Report Second Quarter 2026 Financial Results on July 30, 20266.7.2026 16:00:00 EEST | Press release

Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced it will report earnings after market close on July 30, 2026. The company will host a conference call and webcast on that date to discuss the second quarter 2026 results and the second half 2026 outlook at 5:00 p.m. Eastern / 2:00 p.m. Pacific time. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706560476/en/ Rimini Street to Report Second Quarter 2026 Financial Results on July 30, 2026 A live webcast of the event will be available on Rimini Street’s Investor Relations site via the Rimini Street IR events link and directly via the webcast link. Dial-in participants can access the conference by dialing 1-800-836-8184. A replay of the webcast will be available for one year following the event. About Rimini Street, Inc. Rimini Street, Inc. (Nasda

Orion and Shilpa Medicare Expand Partnership to Develop and Supply Nivolumab Biosimilar for Europe6.7.2026 16:00:00 EEST | Press release

Shilpa Medicare Limited announced that its wholly owned subsidiary, Shilpa Biologicals Private Limited, has entered into a co-development and supply agreement with Orion Corporation for intravenous (IV) nivolumab biosimilar referencing one of the world’s most widely used cancer immunotherapies to widen patient access across Europe. Nivolumab helped usher in the era of immuno-oncology, transforming the outlook for patients with cancers such as melanoma and lung cancer. As the originator approaches loss of exclusivity in Europe, this partnership aims to put a high-quality, EU-GMP-manufactured nivolumab biosimilar within reach of more patients, reducing healthcare burden. In 2025, Nivolumab recorded sales of approximately USD4.1 billion (Source: IQVIA/IMS) Europe — underscoring the scale of the opportunity. Under the agreement, Orion will hold the exclusive rights to register, market, distribute and sell the nivolumab biosimilar across Europe. Shilpa Biologicals will lead product developm

No-Loss Trading Platform UpsideOnly Surpasses 100,000 Users Within Weeks of Launch6.7.2026 15:48:00 EEST | Press release

Perpetuals.com Ltd (Nasdaq: PDC), today announced that UpsideOnly, its risk-free trading and market prediction platform, has seen a surge in new user sign-ups, surpassing the important milestone of 100,000 traders within weeks of its launch on May 19. UpsideOnly lets users make predictions about where global equity, commodity, forex, and crypto markets are heading without ever placing a real trade themselves. Perpetuals uses its own capital to trade on the strongest signals identified by its proprietary AI. If those trades win, Perpetuals shares the profits with the users who helped generate the signal. If the trade doesn’t make money, users lose nothing. Reaching 100,000 users so quickly after launching is a reflection of the enormous demand for a platform that flips the traditional retail trading model on its head, with early platform data showing strong engagement across asset classes, geographies and user activity: Users from more than 180 different countries $38.4 billion in cumul

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye